GlassScriptPhysician profile
Murugesan Siddhappan
NPI 1104096437
$2,596.35
in general payments reported to CMS, 2019-2025
39 companies · $371 in 2025
The $371 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $273 · 2020: $222 · 2021: $502 · 2022: $483 · 2023: $357 · 2024: $389 · 2025: $371.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,048 · Education: $68.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,047.66 |
| Education | $68.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $442.83 | 2019-2025 | Rybelsus, Ozempic |
| Astellas Pharma US INC | $324.51 | 2020-2025 | Myrbetriq, Veozah |
| Abbvie INC. | $304.44 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $169.45 | 2021-2024 | Jardiance |
| Lilly USA, LLC | $146.79 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $143.92 | 2022-2025 | Caplyta |
| Sanofi-Aventis U.S. LLC | $98.08 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $75.20 | 2019-2025 | Xifaxan |
| Sumitomo Pharma America, INC. | $75.02 | 2023-2024 | Gemtesa |
| Amgen INC. | $74.28 | 2020-2024 | Otezla, Repatha, Prolia |
| Janssen Pharmaceuticals, INC | $54.99 | 2019 | |
| Sunovion Pharmaceuticals INC. | $52.33 | 2019-2022 | |
| Exact Sciences Corporation | $46.55 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Glaxosmithkline, LLC. | $42.46 | 2023 | Arexvy, Shingrix, Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $39.72 | 2022 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $38.12 | 2024 | |
| Allergan, INC. | $37.78 | 2020 | |
| Avanir Pharmaceuticals, INC. | $34.00 | 2019 | |
| Arbor Pharmaceuticals, INC. | $33.23 | 2020-2021 | |
| Pfizer INC. | $31.04 | 2023-2025 | |
| Corcept Therapeutics | $30.85 | 2025 | Korlym |
| Genentech USA, INC. | $28.25 | 2020-2021 | |
| Nevro Corp. | $21.66 | 2022 | |
| Tonix Medicines, INC. | $20.69 | 2025 | Tonmya |
| Dexcom, INC. | $20.29 | 2023 | Dexcom G6 Transmitter |
| Medtronic, INC. | $19.00 | 2025 | Inceptiv |
| Lundbeck LLC | $18.83 | 2025 | Vyepti |
| Neurocrine Biosciences, INC. | $17.44 | 2023 | Ingrezza |
| Xeris Pharmaceuticals, INC. | $16.14 | 2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $16.05 | 2023 | |
| Novartis Pharmaceuticals Corporation | $15.84 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $15.16 | 2024 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $14.33 | 2020 | |
| Eisai INC. | $13.38 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $13.31 | 2021 | |
| Biogen, INC. | $13.29 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $13.06 | 2023 | Farxiga |
| Ucb, INC. | $12.75 | 2021 | |
| Mylan Specialty L.P. | $11.29 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Murugesan Siddhappan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.